Efficacy and Safety of LFG316 in Transplant Associated Microangiopathy (TAM) Patients
Status:
Terminated
Trial end date:
2017-06-30
Target enrollment:
Participant gender:
Summary
This was a randomized, SoC-controlled, open-label, multi-center study in patients with TAM
after hematopoietic precursor cell transplantation (HPCT) .
Study consisted of up to 28 days of screening period, 16 weeks treatment period that can be
extended to 45 weeks.Approximately 40 patients was to be randomized to receive SoC or LFG316
plus SoC. Patients was included in the study if they have diagnosis of TAM and poor
prognostic markers. This trial was terminated: LFG316, a monoclonal antibody inhibitor of
complement factor 5 (C5), had been studied in seven patients with transplantation-associated
microangiopathy (TAM). Due to low confidence of clinical benefit, this study was closed